Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 2

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 2
---
 of the Resale Shares. We will pay the expenses (except brokerage fees and
commissions and similar expenses) incurred in registering the Resale Shares, including legal and accounting fees. See “Plan of
Distribution.”

Our Class A Ordinary Shares currently trade on The Nasdaq Capital Market
under the symbol “NIVF.” The last reported closing price of our Class A Ordinary Shares on June 2, 2025 was $1.72.

We qualify as a “foreign
private issuer,” as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or the Securities Act, and are a “controlled
company” as defined under the Listing Rules of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”),
thus we are eligible for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate
governance rules.

NewGenIvf Group Limited (“NewGenIvf,”
“Company,” “our,” “we,” or “us”) is a British Virgin Islands holding company with our
operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited) and in Asia (Hong
Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia). Under this holding company structure, investors are purchasing equity interests
in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands and Asian operating
subsidiaries. Substantially all of NewGenIvf’s operations and assets are based in Thailand, Cambodia and Kyrgyzstan. As a result,
its businesses and operations are subject to the changing economic conditions prevailing from time to time in such countries.

On December 11, 2024,
NewGenIvf announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (“EWIHL”) for
a reverse merger, in which EWIHL would, on completion, hold approximately 61.6% of NewGenIvf’s equity (the “EWIHL Proposed
Transaction”). The completion of the EWIHL Proposed Transaction is subject to, among other matters, the completion of due diligence,
the delivery of draft audited financials for the years ended 2023 and 2024 (the “Draft Financials”) of EWIHL by March 31,
2025, and the negotiation of a definitive agreement. On March 31, 2025, NewGenIvf